公开(公告)号：US20050107611A1

公开(公告)日：2005-05-19

申请号：US10499146

申请日：2002-12-19

申请人： Barbara Matuszczak ,  Christa Muller

发明人： Barbara Matuszczak ,  Christa Muller

IPC分类号： A61K31/4985 ,  A61P1/18 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P11/06 ,  A61P11/08 ,  A61P11/16 ,  A61P13/12 ,  A61P17/02 ,  A61P25/00 ,  A61P25/08 ,  A61P25/16 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/36 ,  A61P37/04 ,  A61P37/08 ,  C07D487/04 ,  C07D487/14

CPC分类号： C07D487/04

摘要： The invention relates to derivatives of the pyrazoyl[1,2,4]triazolo[4,3-α]quinoxaline according to formula (1), or of its analog in the form of the pyrazolyl-substituted tetrazolo[1,5-α]quinoxalines according to formula (2). The substances according to formula 1 or 2, in this form or in the form of their pharmaceutically acceptable salts, are suitable as active agents, especially as adenosine receptor ligands.

摘要翻译： 本发明涉及式（1）的吡唑并[1,2,4]三唑并[4,3-a]喹喔啉的衍生物，或其吡唑基取代的四唑并[1,5-α ]喹喔啉。 根据式1或2的物质，以这种形式或其药学上可接受的盐的形式，适合作为活性剂，特别是作为腺苷受体配体。

公开(公告)号：US20060135489A1

公开(公告)日：2006-06-22

申请号：US10524147

申请日：2004-07-01

申请人： Barbara Matuszczak ,  Manfred Windisch

发明人： Barbara Matuszczak ,  Manfred Windisch

IPC分类号： A61K31/60 ,  A61K31/355 ,  C07D311/04

CPC分类号： C07D405/12 ,  C07D311/72

摘要： Compounds in the form of their racemates, enantiomers or diastereomers with general formula I in which R stands for the unchanged portion of a variable pharmaceutical active ingredient molecule, B stands for a spacer, and Toc with the formula and R′, R″ and R′″ are equal to H or methyl stands for tocopherol and A stands for C═X, SOm, X or CH2, whereby X is equal to 0, S or NR1 (when n≧1) or S or NR1 (when n=0), and B means a grouping X—R2—Y with Y equal to C═X, SOm or C(XR3)R4, and n is equal to 0 to 6, and m stands for 1 or 2, whereby R1 stands for H, C1 to C10-alkyl, Het or an aryl or Het radical that is bonded via a C1 to C6-spacer, and whereby R2 is selected from the group alkylene, arylene or Het spacers and combinations thereof, whereby the latter are linked to one another either directly or via radical A or via grouping Xo-A-Xp, whereby o and p are equal to 0, 1 or 2, and the latter can be the same or different, and whereby R3 and R4 stand for H, C1 to C10-alkyl, Het or an aryl or Het radical that is bonded via a C1 to C6 spacer.

摘要翻译： 其具有通式I的外消旋物，对映异构体或非对映体形式的化合物，其中R表示可变的药物活性成分分子的不变部分，B表示间隔基，且具有式R'，R“的Toc和 R“等于H或甲基代表生育酚，A代表CX，SO x，X或CH 2，其中X等于0，S或 NR 1（当n> = 1时）或S或NR 1（当n = 0时），B表示分组XR < Y，Y等于CX，SO m或C（XR 3）R 4，n等于0至6，m 代表1或2，其中R 1代表H，C 1至C 10 - 烷基，Het或芳基或Het基团，其中 通过C 1至C 6 - 间隔键合，由此R 2选自亚烷基，亚芳基或Het间隔基和组合 其中后者直接地或经由基团A或通过分组X